FDA Web site explains agency operations to public

Jan 12, 2010

(AP) -- The Food and Drug Administration is launching a new Web site explaining its operations to consumers as part of a broader effort to rebrand itself as a more accessible agency.

The Web site, dubbed 'FDA Basics,' features short videos about the agency as well as conversations with leaders.

The FDA has long operated under strict confidentiality rules because its scientists handle reams of proprietary information from food, drug and device companies.

However, the FDA's operating style has come under fire in recent years from critics who have charged that the agency is too slow to disclose drug safety issues.

FDA Commissioner Margaret Hamburg says the agency must be more accessible to the public.

Explore further: Amgen misses 1Q views as higher costs cut profit

More information: http://www.fda.gov/AboutFDA/Basics

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA issues supplement rules

Jun 23, 2007

The U.S. Food and Drug Administration has issued new government standards for the manufacture of vitamins and dietary supplements.

FDA begins major hiring initiative

Apr 30, 2008

The U.S. Food and Drug Administration says it is starting a major hiring initiative designed to fill more than 1,300 public health positions.

FDA launches plan to curb accidental overdoses

Nov 04, 2009

(AP) -- The Food and Drug Administration is launching a program to try and prevent millions of accidental drug overdoses that occur each year due to medication errors, misuse and other problems.

FDA: New warning needed for Chantix

Feb 03, 2008

The U.S. Food and Drug Administration Friday called for increased awareness of the health risks of the smoking cessation drug varenicline.

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

Man among first in US to get 'bionic eye' (Update)

A degenerative eye disease slowly robbed Roger Pontz of his vision. Diagnosed with retinitis pigmentosa as a teenager, Pontz has been almost completely blind for years. Now, thanks to a high-tech procedure ...